A retrospective analysis of electronic health records reports an association between taking glucosamine—a commonly used supplement for joint pain—and worse outcomes in people with Alzheimer’s disease and those at risk for dementia. The study finds that individuals with Alzheimer’s who took glucosamine have a higher likelihood of death within five years than those who did not, with figures reported as about 25% higher risk. Other coverage also describes the supplement as being linked to faster progression, including worsening from mild cognitive impairment to Alzheimer’s, though details vary by framing across outlets. ScienceDaily reports that the researchers also identified biological “clues” that may help explain the observed pattern. The reports emphasize that the findings come from observational data rather than randomized clinical trials, meaning they cannot prove that glucosamine directly causes faster disease progression. Still, the study raises questions about the safety of glucosamine use for older adults and people with cognitive impairment, with calls for further research to confirm the relationship and clarify mechanisms.